Natera price target raised to $85 from $75 at BTIG

BTIG raised the firm’s price target on Natera (NTRA) to $85 from $75 and keeps a Buy rating on the shares after the company won a preliminary injunction order in a patent infringement case against NeoGenomics (NEO). The injunction bars NeoGenomics from making, using, selling or offering for sale in the U.S. its RaDaR MRD test, barring certain exceptions, and marks Natera’s second major legal victory for Signatera in the month of December, the analyst tells investors. The firm is making no changes to revenue or earnings estimates for either Natera or NeoGenomics, but is applying a higher multiple on its 2025 revenue estimate.